Groundbreaking study leverages Seer’s latest technology to unearth early cancer biomarkers via deep, unbiased mass spectrometry-based proteomics.
Seer’s Proteograph ONE Assay promises accelerated analysis and reduced costs, paving the way for large-scale proteomics studies.
REDWOOD CITY, Calif., June 01, 2025 – Seer, Inc. (Nasdaq: SEER), a pioneer in deep, unbiased proteomic insights, and Korea University, a leading research institution, are joining forces on a population-level study that could revolutionize early cancer detection. The initiative is designed to identify novel blood-based biomarkers, potentially leading to improved diagnostics for young adults in their 20s and 30s. The study will utilize Seer’s newly launched Proteograph® ONE Assay and SP200 Automation Instrument, coupled with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer. This marks the first large-scale plasma proteomics undertaking of its kind to harness mass spectrometry and AI-driven analytics to enhance cancer detection and patient outcomes.
This pioneering project will analyze 20,000 plasma samples, including 15,000 from cancer patients and 5,000 from healthy controls. The samples will be sourced from prominent Korean cancer institutions, including Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. This ambitious three-year study is supported by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which focuses on funding high-impact health research.
“We explored several options to expand the dynamic range of the plasma proteome—including attempts to replicate Seer’s Proteograph platform—and ultimately, Seer’s assay was the only solution capable of delivering the depth, scale, and, crucially, reproducibility needed for this ambitious study,” says Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. “The unique combination of Seer’s latest platform and CPGR’s proprietary dual online liquid chromatography technology allows us to conduct research at a population scale that would otherwise be incredibly complex and time-consuming. This collaboration represents a significant step towards developing AI-powered diagnostics that could fundamentally change how we detect and treat cancer in younger adults.”
The study leverages deep proteomic analysis to pave the way for a new generation of diagnostics that are more sensitive, scalable, and personalized. Ultimately, it aims to promote earlier interventions and improved survival rates in young adult cancer patients globally.
A Technological Leap for Population-Scale Proteomics
At the heart of this project is Seer’s Proteograph ONE workflow, unveiled this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically elevates the scale and efficiency of proteomic analysis by:
- Processing over 1,000 samples per instrument per week
- Requiring just a single mass spectrometry injection per sample
- Completing 80-sample batches efficiently
- Identifying up to ten times more proteins than traditional mass spectrometry methods
“Korea University selected Seer’s new Proteograph ONE workflow to be the foundation for this vital, forward-thinking initiative to unlock the full potential of proteomics in population-scale research,” says Omid Farokhzad, Chair and CEO of Seer. “We’re excited to help define a new era of diagnostics that will transform how diseases like cancer are detected and managed worldwide.”
Also instrumental to the study is Thermo Scientific’s Orbitrap Astral MS—the industry’s leading mass spectrometer for proteomic research. The combined power of the Proteograph offerings and the Orbitrap Astral MS facilitates deep, full-range plasma proteome analysis at higher speeds, enabling breakthrough discoveries in extensive population studies.
“When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and the Proteograph ONE workflow provide a robust solution for driving groundbreaking research,” notes Dan Shine, senior vice president and president of analytical instruments at Thermo Fisher Scientific. “We are proud to be a part of initiatives like this, empowering early detection and driving precision medicine forward.”
These next-generation offerings represent a considerable evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency needed to make population-level proteomics practical and accessible. The collaboration with Korea University underscores the real-world impact of this core technology, demonstrating how deep, unbiased proteomic insights, powered by Seer’s platform, are now able to inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics, ultimately redefining precision medicine.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the benchmark in deep, unbiased proteomics, delivering insights with previously unattainable scale, speed, precision, and reproducibility. Seer’s Proteograph Product Suite uniquely incorporates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software. Traditional proteomic technologies have been hindered by inconsistent data, limited throughput, and complex processes, but Seer’s robust and scalable workflow consistently generates biological insights that others cannot replicate. Seer’s products are for research use only and are not for diagnostic procedures.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/1468.html
